文献詳細
文献概要
特集 Precision Medicine—個別化医療を目指した遺伝子診断と新治療の知見 Ⅰ悪性脳腫瘍
低悪性度神経膠腫
著者: 武笠晃丈1
所属機関: 1熊本大学大学院生命科学研究部脳神経外科学講座
ページ範囲:P.8 - P.18
文献購入ページに移動Point
・中枢神経系腫瘍のWHO分類が2021年に改訂されて第5版となり,低悪性度神経膠腫の診断名にも大きな変更が加えられた.
・成人の低悪性度神経膠腫はIDH 変異を有する星細胞腫・乏突起膠腫であり,分子異常に基づいて明確に診断することが重要である.
・IDH変異を標的とした標的治療が開発途上にあり,IDH阻害薬の有効性と臨床応用へ期待が集まっている.
・中枢神経系腫瘍のWHO分類が2021年に改訂されて第5版となり,低悪性度神経膠腫の診断名にも大きな変更が加えられた.
・成人の低悪性度神経膠腫は
・IDH変異を標的とした標的治療が開発途上にあり,IDH阻害薬の有効性と臨床応用へ期待が集まっている.
参考文献
1)Parsons DW, et al:An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-1812, 2008
2)Cancer Genome Atlas Research Network, et al:Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372:2481-2498, 2015
3)Suzuki H, et al:Mutational landscape and clonal architecture in grade Ⅱ and Ⅲ gliomas. Nat Genet 47:458-468, 2015
4)Dang L, et al:Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:739-744, 2009
5)Noushmehr H, et al;Cancer Genome Atlas Research Network:Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17:510-522, 2010
6)Capper D, et al:Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20:245-254, 2010
7)Takami H, et al:Revisiting TP53 mutations and immunohistochemistry--a comparative study in 157 diffuse gliomas. Brain Pathol 25:256-265, 2015
8)Jenkins RB, et al:A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66:9852-9861, 2006
9)Arita H, et al:Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol 126:267-276, 2013
10)Killela PJ, et al:TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 110:6021-6026, 2013
11)Ikemura M, et al:Utility of ATRX immunohistochemistry in diagnosis of adult diffuse gliomas. Histopathology 69:260-267, 2016
12)Brennan CW, et al;TCGA Research Network:The somatic genomic landscape of glioblastoma. Cell 155:462-477, 2013
13)Ueki K, et al:Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. Clin Cancer Res 8:196-201, 2002
14)Aoki K, et al:Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol 20:66-77, 2018
15)Appay R, et al;POLA Network:CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro Oncol 21:1519-1528, 2019
16)Shirahata M, et al:Novel, improved grading system(s)for IDH-mutant astrocytic gliomas. Acta Neuropathol 136:153-166, 2018
17)Satomi K, et al:Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma. Mod Pathol 34:688-700, 2021
18)Gonzalez Castro LN, Wesseling P:The cIMPACT-NOW updates and their significance to current neuro-oncology practice. Neurooncol Pract 8:4-10, 2021
19)Louis DN, et al:The 2021 WHO Classification of Tumors of the Central Nervous System:a summary. Neuro Oncol 23:1231-1251, 2021
20)Ichimura K, et al:IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 11:341-347, 2009
21)Mukasa A, et al:Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients. Cancer Sci 103:587-592, 2012
22)Yan H, et al:IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765-773, 2009
23)Eckel-Passow JE, et al:Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372:2499-2508, 2015
24)Brat DJ, et al:cIMPACT-NOW update 5:recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol 139:603-608, 2020
25)Clark VE, Cahill DP:Extent of resection versus molecular classification:what matters when? Neurosurg Clin N Am 30:95-101, 2019
26)Choi C, et al:2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med 18:624-629, 2012
27)Arita H, et al:Lesion location implemented magnetic resonance imaging radiomics for predicting IDH and TERT promoter mutations in grade Ⅱ/Ⅲ gliomas. Sci Rep 8:11773, 2018
28)Chang K, et al:Residual convolutional neural network for the determination of IDH status in low- and high-grade gliomas from MR imaging. Clin Cancer Res 24:1073-1081, 2018
29)Patel SH, et al:T2-FLAIR mismatch, an imaging biomarker for IDH and 1p/19q status in lower-grade gliomas:a TCGA/TCIA project. Clin Cancer Res 23:6078-6085, 2017
30)Jain R, et al:“Real world” use of a highly reliable imaging sign:“T2-FLAIR mismatch” for identification of IDH mutant astrocytomas. Neuro Oncol 22:936-943, 2020
31)Mukasa A:Genome medicine for brain tumors:current status and future perspectives. Neurol Med Chir(Tokyo) 60:531-542, 2020
32)Kayabolen A, et al:IDH mutations in glioma:double-edged sword in clinical applications? Biomedicines 9:799, 2021
33)Waitkus MS, Yan H:Targeting isocitrate dehydrogenase mutations in cancer:emerging evidence and diverging strategies. Clin Cancer Res 27:383-388, 2021
34)Rohle D, et al:An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340:626-630, 2013
35)Mellinghoff IK, et al:Ivosidenib in isocitrate dehydrogenase 1-mutated advanced glioma. J Clin Oncol 38:3398-3406, 2020
36)Mellinghoff IK, et al:Vorasidenib, a dual inhibitor of mutant IDH1/2, in recurrent or progressive glioma;results of a first-in-human phase I trial. Clin Cancer Res 27:4491-4499, 2021
37)Barthel FP, et al;GLASS Consortium:Longitudinal molecular trajectories of diffuse glioma in adults. Nature 576:112-120, 2019
38)Friedrich M, et al:Perspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas. Curr Opin Oncol 30:368-374, 2018
39)Schumacher T, et al:A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 512:324-327, 2014
40)Tateishi K, et al:Extreme vulnerability of IDH1 mutant cancers to NAD+ depletion. Cancer Cell 28:773-784, 2015
掲載誌情報